UNLISTED Brisbane peptide company Xenome has won a US patent battle over the company’s novel class of norepinephrine transporter (NET) inhibitors. The patent was reissued this week following a ruling on a patent interference process between Xenome and an unnamed US company.
You are not logged in or not authorised to view this page.
